Pharming Group Swings to Profit, Reports 27% Revenue Growth and Positive Cash Flow in 2025
Summary
Pharming Group reported strong fourth quarter and full year 2025 financial results, with full-year total revenues increasing 27% to US$376.1 million. Crucially, the company achieved an operating profit of US$25.8 million and generated US$54.7 million in net cash flow from operations in 2025, marking a significant turnaround from losses and negative cash flow in the prior year. This strong performance was driven by continued growth of RUCONEST and accelerating demand for Joenja. The company also provided 2026 total revenue guidance of US$405.0 - US$425.0 million, representing 8% to 13% growth. This financial inflection point demonstrates strong operational execution and a shift to sustainable profitability and cash generation, which is highly material for investors. Traders will be watching the continued growth of Joenja and the company's progress towards its 2026 revenue guidance and pipeline milestones.
At the time of this announcement, PHAR was trading at $15.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.50 to $21.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.